Lilly's 13 acquisitions in 2026, worth about $32B, are recycling cash back to at least 50 biotech venture investors.
Trump strikes MFN drug-pricing deals with 9 more drugmakers as Incyte joins quietly; Oz says 600K seniors signed up for CMS ...
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward ...
Google's Gemini now lets users book appointments via Zocdoc. Google Health Chief Michael Howell and Zocdoc CEO Oliver Kharraz ...
Roche licenses Simcere Zaiming's preclinical trispecific T cell engager SIM0660 for $75M upfront, up to $1.53B in biobucks, its second China biotech deal this month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results